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 2011 EMBO Molecular MedicineESR1 is one of the most important transcription factors and therapeutic targets in
breast cancer. By applying systems-level re-analysis of publicly available gene
expression data, we uncovered a potential regulator of ESR1. We demonstrated
that orphan nuclear receptor NR2E3 regulates ESR1 via direct binding to the ESR1
promoter with concomitant recruitment of PIAS3 to the promoter in breast
cancer cells, and is essential for physiological cellular activity of ESR1 in estrogen
receptor (ER)-positive breast cancer cells. Moreover, expression of NR2E3 was
significantly associated with recurrence-free survival and a favourable response
to tamoxifen treatment in women with ER-positive breast cancer. Our results
provide mechanistic insights on the regulation of ESR1 by NR2E3 and the clinical
relevance of NR2E3 in breast cancer.INTRODUCTION
Nuclear receptors (NRs) are one of the largest families of
transcription factors in metazoans and govern expression of
various genes involved in a wide range of reproductive,
developmental, metabolic and immunological responses
(Gronemeyer et al, 2004; Hegele, 2005; McKenna et al, 2009).exas M. D. Anderson
M University Health
exas M. D. Anderson
. D. Anderson Cancer
rmaceutical Sciences,
arch, Ewha Woman’s
acology, Texas A&M
1 713 563 4235;Because they contribute to physiologic and pathologic condi-
tions in many organs, NRs have been recognized as one of the
most important and successful therapeutic targets for various
human diseases, including cancer (Gronemeyer et al, 2004;
Hegele, 2005). While much is known about molecular
mechanisms of certain NRs, relatively little is known about
the complex network of crosstalk among NRs that may play a
key role in their regulation of many normal and pathologic
conditions. The large number of NRs (48 in humans) makes it
time-consuming and difficult to discover such a network using
conventional molecular techniques alone (Bookout et al, 2006;
Yang et al, 2006).
Genome-wide approaches using high-throughput technolo-
gies have been used to explore potential NR networks. In studies
by Bookout et al (2006) and Yang et al (2006), expression
patterns for all NRs were collected from all mouse organs to gain
new insights on integrated NR networks in various organs
(Bookout et al, 2006; Yang et al, 2006). In two different studies,
the genome-wide chromatin-immunoprecipitation (ChIP) assay
revealed FOXA1 as a new estrogen receptor (ESR1) partner
bound to the ESR1 promoter region in breast cancer cells (Carroll
et al, 2005, 2006).Wang et al (2009) used a similar approach and
uncovered UBEC2, which functions as an androgen receptor
(AR) downstream target gene in prostate cancer.EMBO Mol Med 4, 52–67 www.embomolmed.org
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available high-throughput data has facilitated identification of
genes having an unexpected association with malignant
diseases or with therapeutic targets of diseases (Carroll et al,
2006; Tomlins et al, 2008). Thus, to uncover a potential network
of NRs in human cancer or novel interplay among NRs, we
conducted a systems-level analysis of publicly available gene
expression data from National Cancer Institute-60 (NCI-60) cell
lines (Scherf et al, 2000). The NCI-60 cell lines consist of 60
human cancer cell lines derived from nine different tumour
types including colorectal, renal, ovarian, breast, prostate, lung
and central nervous system tumours, as well as leukemia and
melanoma (Monks et al, 1991). NCI-60 cell lines are the most
extensively characterized panel of cancer cell lines and are used
for drug screening and many pilot experiments (Shoemaker,
2006).
Herewe show for the first time that a systems-level analysis of
publicly available data uncovered an unexpected relationship
between two NRs, namely NR2E3 and ESR1. Furthermore, we
show that NR2E3 is a novel regulator of ESR1 expression in
breast cancer cells and a potential predictive marker for
response to tamoxifen for women with ESR1-positive and
node-negative breast cancer.RESULTS
Systems-level analysis of genome-wide gene expression data
from NCI-60 cell lines uncovered novel interactions among
nuclear receptors in breast cancer
To uncover potential interacting network of NR genes and to
generate testable hypotheses, we have used publicly available
gene expression data from NCI-60 cell lines that have been used
extensively as an exploration data set (Amundson et al, 2008;
Hsu et al, 2009; Park et al, 2010; Potti et al, 2006; Reinhold et al,
2010;Wang & Li, 2009). We first tried to uncover an NR network
using direct correlation of expression patterns of NRs across
NCI-60 cell lines but were not able to produce a recognizable
network with a higher degree of interaction among NRs
(Fig 1A). Since all NRs are transcription factors that regulate
expression of many genes, we hypothesized that expression
patterns of direct or indirect target genes regulated by NRs
would be are well correlated with patterns of NR expression.
Therefore, we identified genes whose expression was signifi-
cantly correlated with those of NR genes in NCI-60 cell lines as
potential downstream targets of NRs. After establishing a
Pearson’s correlation test p-value of less than 0.001 as being
indicative of significance with expression patterns of the NR
genes, we generated correlated gene lists of 45 NRs (Fig 1B). As
expected, many of the identified correlated genes were
previously identified as downstream targets of NR genes. For
example, expression of GATA3, a well-known downstream
target of ESR1 (Eeckhoute et al, 2007), was highly correlated
with expression of ESR1 (r¼ 0.76, p¼ 3.09 1012).
Using 45 NR-correlated gene lists comprised of 86–4580
genes, we investigated how many genes in each NR-correlated
gene lists were shared in other NR-correlated gene lists, and thenwww.embomolmed.org EMBO Mol Med 4, 52–67we generated the matrix of the shared gene number of each NR
across all NRs. To generate a simple but comprehensive network
of relationships among NRs, we applied hierarchical clustering
to the shared gene number data (Fig 1C). Of interest, the highest
number of correlated genes was shared among ESR1, PPARA,
NR2C2, THRA, ESRRA, NR2E3 and HNF4A. Out of 7 NRs,
expression patterns of HNF4A, NR2E3, THRA and PPARA were
directly correlated with ESR1 expression in NCI-60 cell lines
(Fig 1D), indicating that these NRsmight be directly or indirectly
involved in ESR1-signalling pathways.
Since biological and pathological roles of ESR1 have been best
characterized in breast cancer, next we performed correlation
analysis using gene expression data from breast cancer patients
[Netherands Cancer Institute (NKI) data set, n¼ 295] (van de
Vijver et al, 2002). Of the four NRs selected from the NCI-60 cell
lines, only the expression of NR2E3 remained significant
(r¼ 0.69, p¼ 1.59 109) and correlated positively with the
expression of ESR1 in the NKI breast cancer cohort (Fig 2A). A
strong correlation with ESR1 was observed in another large
breast cancer cohort [University of North Carolina (UNC)
cohort, n¼ 380, r¼ 0.667, p¼ 2.2 1016] (Fig 2B; Hu et al,
2006; Oh et al, 2006; Parker et al, 2009). In addition, more than
50%ofNR2E3 correlated genes overlappedwith those of ESR1 in
gene expression data from both the NKI and UNC cohorts
(Fig 2C–H). Taken together, the concordant and significant
association of NR2E3 with ESR1 in multiple data sets suggests
that NR2E3 may be involved in regulation of ESR1-mediated
gene expression and pathways in breast cancer.
NR2E3 directly regulates expression of ESR1
NR2E3 was first identified as a photoreceptor-specific nuclear
receptor (PNR; Kobayashi et al, 1999; Takezawa et al, 2007),
that is necessary for proper eye development and maintenance
by regulating the expression of cone-specific and rod-specific
genes in retinal cells (Onishi et al, 2009). Mutations in NR2E3
have been linked to many degenerative eye diseases including
enhanced S-cone sensitivity syndrome, Goldmann-Favre syn-
drome and clumped pigmentary retinal degeneration (Schor-
deret & Escher, 2009).
Since little is known about the function of NR2E3 in breast
cancer, we investigated possible roles of NR2E3 related to the
ESR1-signalling pathway using NR2E3-specific small hairpin
RNA (shRNA) in estrogen receptor (ER)-positive breast cancer
MCF-7 cells (Fig 3A). Surprisingly, when expression of NR2E3
was silenced by shRNA, expression of ESR1 and its downstream
targets (GATA3, PGR, CCND1 and TFF1) were also significantly
downregulated (Fig 3B); reduced expression of ESR1 and its
downstream targets was also validated at the protein level
(Fig 3E). The effect of silencing NR2E3 expression on ESR1 and
its downstream targets was also highly reproducible in another
ER-positive breast cancer cell line: T47D (Fig 3C and D). It is
interesting to point out that expression of FOXA1was not altered
after silencing NR2E3expression in MCF-7 cells while its
expression was down-regulated in T47D cells, suggesting that
additional regulatory mechanisms for expression of FOXA1
might exist in MCF-7 cells. Transcriptional activity of ESR1 was
also diminished by small hairpin NR2E3 (shNR2E3; Fig 3F). 2011 EMBO Molecular Medicine 53
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Figure 1. NR gene network in NCI-60 cell lines.
A. Out of 48 human NR genes, expression data of 45 NRs were available in publically available NCI-60 data set and used for hierarchical clustering analysis. The
data are presented in matrix format in which rows represent individual gene and columns represent each cell lines. Each cell in the matrix represents the
expression level of a gene feature in an individual cancer cell. The red and green colour in cells reflects relative high and low expression levels in log 2
transformed scale.
B. Establishing a Pearson’s correlation test p-value of less than 0.001 as indicative of in trans significance with expression patterns of the potential downstream
genes, we generated 45 gene sets of in trans correlated genes as putative targets genes for each NR gene; these gene sets were comprised of 86–4580 genes
(median¼ 1275).
C. By cross-comparison of correlated genes in all 45-gene lists, we generated secondary lists reflecting overlap of correlated genes among NR genes. These
secondary gene lists are presented in matrix format, and hierarchical clustering analysis was performed with the number of correlated genes overlapped
between NR. Heat maps indicate the number of genes overlapped between NRs.
D. Only positively correlated genes are presented (2255 gene features). With a cut-off of Pearson’s correlation test p-value of less than 0.001, expression of 2255
gene features was positively correlated with that of ESR1. Of six genes whose correlated genes significantly overlapped with those of ESR1, expression of four
genes (HNF4A, NR2E3, THRA and PPARA) was significantly correlated with expression of ESR1.
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Figure 2. NR2E3 is highly correlated with ESR1 in breast cancer patients.
A. With a cut-off of Pearson’s correlation test p-value of less than 0.001, expression of 6753 gene features were correlated with that of ESR1 in the NKI breast
cancer data set (n¼ 295). Of six genes whose correlated genes significantly overlapped with those of ESR1, expression of NR2E3 was only positively
correlated with ESR1 expression.
B. Correlation of ESR1 and NR2E3 expression in UNC breast cancer patient cohort. Scatter plots between ESR1 and NR2E3 in UNC cohort (n¼ 380).
C-D. ESR1-corelated genes (C) or NR2E3 correlated genes (D) in NKI cohort were clustered according to their expression patterns.
E. Venn diagram of comparison of two correlated genes in NKI cohort.
F-G. ESR1-corelated genes (F) or NR2E3 correlated genes (G) in UNC cohort were clustered according to their expression patterns.
H. Venn diagram of comparison of two correlated genes in UNC cohort.
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Figure 3. NR2E3 regulates ESR1 function in breast
cancer cells.
A-B. MCF-7 cells were stably transfected with shNR2E3
or control shRNA (shCon). Total RNA from
indicated cell extracted and analysed by qRT-PCR
with indicated probe.
C-D. T47D cells were stably transfected with shNR2E3
or shCon. Total RNA and protein from indicated
cell extracts were analysed by qRT-PCR with
indicated probes.
E. MCF-7 cells were stably transfected with shNR2E3
or control shRNA (shCon). Total protein from
indicated cell extracted and analysed by Western
blot with indicated antibody.
F. Stably transfected MCF-7 with shNR2E3 or with
shCon were transfected with ESR1 promoter
construct, and the cells were harvested for
luciferase assay. Values indicated relatively
normalized luciferase activity.
G-H. MCF-7 cells were transiently transfected with
indicated siRNA, and cell lysates were used for
Western blot (G) or for qRT-PCR (H). All results are
shown as mean plus standard deviation (SD) from
three-independent replicates (p< 0.05,
p<0.01 and p< 0.005).
56Furthermore, overexpression of exogenous NR2E3 further
increased expression of ESR1 and its downstream targets as
well as its transcriptional activity in MCF-7 cells (Fig S1 of
Supporting Information), strongly demonstrating that NR2E3
regulates ESR1 expression and subsequent ESR1-mediated
induction of target genes.
Since a previous report had shown that GATA3 mutually
regulates ESR1 (Eeckhoute et al, 2007), we investigated whether
ESR1 could also regulate NR2E3 through an auto-regulatory 2011 EMBO Molecular Medicinefeedback loop. As shown in Fig 3G and H, silencing ESR1
expression did not alter expression of NR2E3 (mRNA and
protein), indicating that NR2E3 is not part of the feedback
regulation loop in the ESR1-signalling pathway.
To test whether regulation of ESR1 expression by NR2E3 is
due to direct binding of NR2E3 on the ESR1 promoter region, we
carried out the luciferase reporter assay tomap the binding region
of the ESR1 promoter using three promoter constructs containing
different lengths of the ESR1 promoter as described (Fig 4A;EMBO Mol Med 4, 52–67 www.embomolmed.org
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Figure 4. NR2E3 maintains ESR1 function via direct binding to ESR1 promoter in breast cancer cells.
A. Diagram of ESR1 gene promoter spanning from 245 to þ212 bp, from 735 to þ212 bp and from 2769 to þ212 bp.
B. MCF-7 cells transiently transfected with indicated ESR1 deletion reporters and NR2E3 construct.
C. MCF-7 cells-stably knocked down by NR2E3 were transiently transfected with indicated ESR1 deletion constructs. Cell lysates were used for measuring
the luciferase activity.
D. Schematic representation of ESR1 promoter region for ChIP assay. Estrogen receptor response element (ERE).
E. ChIP assay was done inMCF-7 or in T47Dwith NR2E3 antibody. Recruitment of NR2E3 to the ESR1 promoter was analysed using primers specific to the ESR1
promoter. IgG was used as an internal control.
F-G. After stably transfecting control and NR2E3-specific shRNA in MCF-7 cells, the total viable cell numbers were determined by Coulter Z1 counter (Beckman
Coulter, Brea, CA). Following stable transfection of shRNAs, the total viable cell numbers were determined after vehicle or E2 treatment with the
indicated dose.
H-I. Expression of CCND1 and TFF1 in shRNA transfected MCF-7 cells after vehicle or E2 treatment for 24 h. Student’s t test (two-tailed) was applied to
estimate the significance of gene expression changes. All results are shown as mean plus standard deviation (SD) from three-independent replicates
(p< 0.05, p<0.01 and p< 0.005). Significant differences in cells were compared with controls.
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~deGraffenried et al, 2002). Transcription activities remained
same in all three constructs of ESR1 promoter (Fig 4B). In
addition, transcription activity in shortest construct (245 ESR1
Luc.) was diminished when expression of NR2E3 was silenced
by shNR2E3 (Fig 4C). These results suggest that the binding sites
reside near and/or inside of the 245 promoter regions. The
outcome of the reporter gene assay was supported by a
subsequent chromatin immunoprecipitation (ChIP) assay. In
agreement with reporter assay, NR2E3 only interact with ESR1
promoter between the250 andþ447 bp regions (Fig 4D and E).
Taken together, our results strongly indicate that NR2E3
regulates ESR1 at the transcriptional level via direct binding
to the ESR1 promoter.
Proliferation of ER-positive breast cancer cells largely
depends on ESR1 responding to estrogen (Ali & Coombes,
2002; Cosman & Lindsay, 1999; Kanavos, 2006). Thus, we
investigated whether NR2E3 is necessary for proliferation of ER-
positive breast cancer cells. As expected, basal-level and
estradiol (E2) induced proliferationwere dramatically decreased
after silencing NR2E3 expression in MCF-7 cells (Fig 4F and G).
In addition, expression of ESR1-dependent genes such as CCND1
and TFF1 was also decreased by shNR2E3 (Fig 4H and I).
Coregulator PIAS3 is required for regulation of ESR1
expression by NR2E3
Many biochemical and genetic studies have demonstrated that
coregulators are critically important for the function of NRs
and the induction of NR-dependent genes (Xu et al, 2009).
Since NR coactivators (NCOAs, also known as steroid receptor
coactivators) are the best-known coregulators of NRs and
interact with diverse NRs in human cancer (Xu et al, 2009), we
first investigated their possible role in regulating ESR1
expression by NR2E3. After silencing NCOA1, 2 and 3 by their
specific siRNA (SMART Pool) in MCF-7 cells, we measured gene
expression of ESR1 and its downstream target genes. While
silencing the expression of the NCOA family genes significantly
downregulated expression of ESR1 downstream target genes,
expression of ESR1 itself was not altered (Fig 5A and B). When
we used different siRNAs to knock down NCOA family
members, the result were significant as shown in Fig S2B andFigure 5. PIAS3 association with ESR1 via NR2E3.
A-B. MCF-7 breast cancer cells were transiently transfected with NCOA1, 2 and 3
indicated samples and used forWestern blot with indicated antibodies (A) and
gene-specific primers as indicated (B). Student t-test (two-tailed) was appl
p< 0.01 and p< 0.05.
C-D. MCF-7 cells were transiently transfected with siPIAS3or siLuc. Total RNA or pr
(D) to detect the indicated mRNA or protein expression levels.
E. MCF-7 cells were transiently transfected with siESR1 or siLuc. Protein from
protein expression levels.
F. ESR1 promoter construct was transfected with indicated constructs after indi
luciferase assay. Values indicated relatively normalized luciferase activity. W
G. Co-IP of NR2E3 with PIAS3 analysed by Western blotting from MCF-7 cells
H. GST-NR2E3 was incubated with His-PIAS3 for 2 h at 48C and then isolated fro
were subjected to immunoblot analysis to NR2E3 or PIAS3.
I. ChIP assay was done in MCF-7 with PIAS3 or NR2E3 antibodies. Recruitment
promoter. IgG was used as an internal control.
J. After MCF-7 cells were transiently transfected with siPIAS3 or siLuc., cells
www.embomolmed.org EMBO Mol Med 4, 52–67C of Supporting Information. This suggests that the NCOAs are
only involved in regulation of ESR1’s transcriptional activity and
do not influence NR2E3-mediated regulation of ESR1 expression
in breast cancer cells.
In retinal cells, the transcriptional activity of NR2E3 is tightly
controlled through interactions with protein inhibitor of
activated STAT3 (PIAS3), which is a coregulator of many
transcription factors (Chung et al, 1997; Jimenez-Lara et al,
2002; Junicho et al, 2000; Onishi et al, 2009). PIAS3, the main
inhibitor of STAT3, is a multifunctional protein that plays a
significant role in the modulation of several key factors such as
NFkB, SMAD and MITF involved in the immune response
pathways (Chung et al, 1997; Jimenez-Lara et al, 2002; Junicho
et al, 2000).
Thus, we next tested whether PIAS3 is essential for regulation
of ESR1 expression byNR2E3 in breast cancer cells. Silencing the
expression of PIAS3 significantly downregulated the expression
of ESR1 and its downstream targets in both MCF-7 and T47D
cells (Fig 5C and D and Fig S3 of Supporting Information). When
different siRNA (SMART Pool) was used to knock down PIAS3
in MCF-7 cells, the result was significant as shown in Fig S4 of
Supporting Information.
We also investigated whether ESR1 regulates PIAS3 via
feedback loop. As shown in Fig 5E, silencing ESR1 expression
did not alter expression of PIAS3 protein, indicating that
PIAS3 is not also part of the feedback regulation loop in the
ESR1-signalling pathway. Because PIAS3 has E3 SUMO ligase
activity, we next investigated whether E3 SUMO ligase activity
of PIAS3 is important for regulation of ESR1 expression by
silencing expression of UBC9 E2 SUMO conjugating enzyme,
essential protein for E3 ligase activity (Sakaguchi et al, 2007).
Silencing of UBC9 expression did not alter transcriptional
activity of ESR1 promoter (Fig 5F), suggesting that it is unlikely
that E3 ligase activity in PIAS3 plays important roles in
regulation of ESR1 expression via NR2E3.
Since PIAS3 is best known as a suppressor of many
transcription factors via direct interactions (Chung et al,
1997), we tested whether PIAS3 directly regulates expression
of ESR1 through interaction with NR2E3 or indirectly regulates
its expression by inhibiting a repressor of NR2E3. Co-specific siRNA Smart Pool or control siLuc. Protein lysates were isolated from
30ng of total RNA from transfected cell lines were analysed by qRT-PCR using
ied to estimate the significance of gene expression changes: p< 0.005,
otein from indicated cell extracts was analysed by qRT-PCR (C) or Western blot
indicated cell extracts was analysed by Western blot to detect the indicated
cated siRNA was transfected withMCF-7 cells, and the cells were harvested for
estern blot shows silencing efficiency of UBC9.
.
m reaction mixture by an immobilized nickel resin. The resulting precipitates
of PIAS3 to the ESR1 promoter was analysed using a primer specific to the ESR1
were used for ChIP assay.
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60immunoprecipitation (IP) experiments from MCF-7 cell lysates
clearly demonstrated direct physical interaction between PIAS3
and NR2E3 (Fig 5G), which are also confirmed by in vitro
association between recombinant NR2E3 and PIAS3 proteins
(Fig 5H).
In addition, the ChIP assay illustrated in Fig 5I showed
that PIAS3 is directly or indirectly recruited to NR2E3 on the
ESR1 promoter region. It is interesting to point out that
interaction with PIAS3 was necessary for binding of NR2E3
to the ESR1 promoter; silencing of PIAS3 expression in MCF-7
cells abolished the binding of NR2E3 to the ESR1 promoter
(Fig 5J). Of note, interaction of NR2E3 with PIAS3 is specific
for ESR1 expression in breast cancer cells, since DHX30/
RetCoR, another NR2E3-interacting coregulator in retina
cells, failed to show interaction with NR2E3 on the ESR1
promoter (Fig 5I).
Clinical relevance of NR2E3 in human breast cancer
Since ESR1 is known to be an important prognostic marker in
breast cancer management (Fisher et al, 1988; Hilsenbeck et al,
1998; Loi et al, 2008; Oh et al, 2006), we tested whether NR2E3
(an upstream regulator of ESR1) is also significantly associated
with prognosis in breast cancer patients. For our analysis,
we used a public database (Gene Expression Omnibus in
the National Center for Biotechnology Information) to retrieve
gene expression data of breast cancer patients. Patients in
the NKI cohort (n¼ 295; van de Vijver et al, 2002) were first
dichotomized according to expression levels of ESR1. As
expected, two groups of breast cancer patients showed a
significant difference in recurrence-free survival (RFS; Fig 6A).
When the patients were dichotomized according to expression
level of NR2E3, RFSs of patients with higher expression of
NR2E3 were significantly better than that of those with lower
expression of NR2E3 (Fig 6B). Furthermore, patients with a
higher expression of both ESR1 and NR2E3 had the best clinical
outcomes, while patients with a lower expression of both ESR1
and NR2E3 had the worst clinical outcomes (Fig 6C). The
association of NR2E3 expression with prognosis also remained
significant in a large independent breast cancer cohort (UNC
cohort, n¼ 380; Hu et al, 2006; Oh et al, 2006; Parker et al, 2009;
Fig 6D–F).
When a patient cohort of all ER-positive breast cancer
[Institut Jules Bordet (IJB) cohort, n¼ 349; Loi et al, 2007, 2008]
was dichotomized by expression levels of ESR1, it was no longer
associated with RFS (Fig 7A), whereas,expression of NR2E3was
still a significant predictor of recurrence in this cohort (Fig 7B).
Since ESR1 is also the best-known predictive marker for
adjuvant therapy with tamoxifen (Kanavos, 2006; Loi et al,
2007), we assessed clinical relevance of NR2E3 expression in
patients with ER-positive breast cancer who received systemic
tamoxifen treatment (subset of IJB cohort, n¼ 263). Unlike
ESR1, which lacks predictive value in ER-positive patients,
expression of NR2E3 was significantly associated with RFS of
patients (Fig 7C and D). This association remained significant
even when only patients with lymph node-negative breast
cancer were considered for analysis (subset of IJB cohort,
n¼ 114; Fig 7E and F), indicating that expression level of NR2E3 2011 EMBO Molecular Medicinemight be useful in predicting the response of ER-positive and
node-negative patients to tamoxifen treatment.
To further validate the association of NR2E3 with prognosis
observed in publicly available data sets, we next carried out
reverse-phase protein array (RPPA) experiments using the
NR2E3-specific antibody in a new breast cancer cohort [M. D.
Anderson Cancer Center (MDACC) cohort, n¼ 575] (Fig S5 of
Supporting Information). As observed in three previous cohorts,
expression of NR2E3 or ESR1 proteins were significantly
associated with prognosis of breast cancer patients, and use
of both ESR1 and NR2E3 expression together greatly improved
the predictability of prognosis (Fig 7G and H and Fig S6 of
Supporting Information). These results strongly indicated that
NR2E3 not only regulates the expression of ESR1 but also may
dictate the clinical behaviour of breast cancer patients
expressing ESR1. Because our previous experiments suggested
that PIAS3 and NR2E3 co-regulates ESR1 expression in breast
cancer cells (Fig 5), we next assessed correlation of expression
patterns among three genes in ER-positive breast cancer patients
(IJB cohort). Expression of three genes is significantly correlated
to each other among patients with breast cancer (Fig S7 of
Supporting Information), suggesting that significant association
of three genes in functional and molecular levels remains same
in clinical data.
We next examined gene networks shared betweenNR2E3 and
ESR1 by comparing gene expression signatures specific to
silencing expression of each gene in MCF-7 cells. The Venn
diagram (Fig 8A) shows that a substantial number of gene
features were identified as downstream targets of both NR2E3
and ESR1, suggesting that a significant part of NR2E3-mediated
biological activity is dependent on ESR1. We next tested the
clinical relevance of the shared signature by applying a
previously established prediction strategy that employs multiple
different algorithms (Fig 8B and Method 1 of Supporting
Information; Lee et al, 2004, 2006). As expected, the shared gene
expression signature was significantly associated with disease
recurrence in breast cancer patients (Figs S8 and S9 of
Supporting Information) when judged by predicted outcomes
of various classifiers. Of interest, the NR2E3-specific gene
expression signature (1847 gene features; Gene list on Table 1 of
Supporting Information) that was independent of ESR1was also
significantly associated with disease recurrence (Fig 8C), suggest-
ing that NR2E3 activity, that is independent of ESR1 might have
important functional roles and prognostic significance in breast
cancer. Gene network analysis revealed several interesting
features that may contribute to prognostic features of NR2E3 in
breast cancer (Fig S10 of Supporting Information).
Since gene expression data from gene-silencing experiments
suggested that NR2E3 might have ESR1-independent functional
roles in breast cancer, we next investigated whether NR2E3
would have clinical relevance in ER-negative breast cancer.
Expression of NR2E3 was not associated with prognosis of
patients with ER-negative breast cancer (Fig 11S of Supporting
Information). In addition, ESR1-independent NR2E3-specific gene
signatures (1847 genes) was not associated with prognosis of
patients with ER-negative breast cancer (Fig 12S of Supporting
Information) when prognostic significance of the signature wasEMBO Mol Med 4, 52–67 www.embomolmed.org
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Figure 6. Expression of NR2E3 is significantly associated with recurrence of breast cancer.
A-C. Breast cancer patients in the NKI cohort (n¼295) were dichotomized by expression of ESR1 (A) orNR2E3 (B) and patient with relative high expression of both
ESR1 and NR2E3 or relative low expression of both ESR1 and NR2E3 were considered for plotting (C).
D-F. Patients in the UNC cohort (n¼ 380) were dichotomized by expression of ESR1 (D) or NR2E3 (E) and patient with relative high expression of both ESR1 and
NR2E3 or relative low expression of both ESR1 and NR2E3 were considered for plotting (F).assessed to only those with ER-negative breast cancer. In
contrast, the signature was significantly associated with
those with ER-positive breast cancer (Fig 13S of Supporting
Information).DISCUSSION
Molecular mechanisms responsible for ESR1-mediated regula-
tion of its downstream target genes (i.e., FOXA1, GATA3,www.embomolmed.org EMBO Mol Med 4, 52–67CCND1 and TFF1) in normal and/or pathological conditions
have been well characterized (Carroll et al, 2005; Eeckhoute
et al, 2007; Krum et al, 2008), however, upstream regulators of
ESR1 and molecular mechanisms for regulating this gene are
poorly understood (Hosey et al, 2007). Our systems-level
exploration of the NR network using publicly available data
uncovered an unexpected interaction between NR2E3 and ESR1,
and our subsequent experiments validated that NR2E3 is novel
upstream regulator of ESR1 and may dictate the clinical
behaviour of ER-positive breast cancer. 2011 EMBO Molecular Medicine 61
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Figure 7. NR2E3 is a prognostic factor in ER-positive patients.
A-B. ER-positive patients in the IJB cohort (n¼349) were dichotomized by expression of ESR1 (A) or NR2E3 (B).
C-D. ER-positive patients who received tamoxifen treatment in IJB cohort (n¼263) were dichotomized by expression of ESR1 (C) or NR2E3 (D).
E-F. ER-positive and node-negative patients who received tamoxifen treatment in IJB cohort (n¼114) were dichotomized by expression of ESR1 (E) or NR2E3 (F).
G-H. Patients in the M. D. Anderson Cancer Center (MDACC) cohort (n¼575) were dichotomized by expression of both ESR1 and NR2E3 proteins. Log-rank test
was applied to estimate the significance of difference.
62In the current study, we have demonstrated that NR2E3 is
essential for expression of ESR1 in ER-positive breast cancer
cells by binding directly to the proximal region of the ESR1
promoter. While searching for transcription coactivators that
interact with NR2E3, we found that PIAS3 [a transcription
coregulator with E3 small ubiquitin-like modifier (SUMO)
ligase activity] is required for both binding of NR2E3 to
the ESR1 promoter and expression of ESR1, as revealed
by siRNA-mediated gene-silencing experiments (Fig 5). Addi-
tional gene-silencing experiments indicated this regulation is 2011 EMBO Molecular Medicineindependent of other canonical coactivators of NRs NCOA1,
2 and 3 (Fig 5B).
The mechanism of action on the ESR1 promoter is similar to
regulation of rod-specific genes by NR2E3 in retinal cells (Onishi
et al, 2009), where PIAS3 enhances the transcriptional activity of
NR2E3. It is currently unknownwhether SUMOylation of NR2E3
by PIAS3 is necessary for its transcriptional activity in breast
cancer cells. However, a previous study has shown that PIAS3-
mediated activation of NR2E3 in retinal cells is independent of
E3 SUMO ligase activity in PIAS3 (Onishi et al, 2009), suggestingEMBO Mol Med 4, 52–67 www.embomolmed.org
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Figure 8. NR2E3-specific gene expression
signatures.
A. Gene expression signature specific to loss of
NR2E3 or ESR1 expression by shRNA or
siRNA in MCF-7 cells. Genes in the Venn
diagram were selected by applying a two-
sample Student’s t-test (p< 0.005). The
green and blue circles represent genes
whose expression patterns are significantly
associated with loss of NR2E3 or ESR1,
respectively.
B. Overall scheme of generation of prediction
models and evaluation of predicted out-
come based on shared gene expression
signature of NR2E3 and ESR1 in MCF-7. A
shared gene expression signature was used
to form a series of classifiers that estimated
the probability of how much the expression
pattern of a particular patient with breast
cancer was similar to the shared signature;
control (Con.) vs. knock down (KD).
C. Kaplan–Meier plots of RFS of breast cancer
patients in the NKI cohort were predicted by
using the ESR1-independent NR2E3 gene
expression signature as a classifier. The
differences between groups were signifi-
cant as indicated (log-rank test). CCP,
compound covariate predictor; 1NN, one
nearest neighbor; 3NN, three nearest
neighbors; NC, nearest centroid; SVM,
support vector machines; and LDA, linear
discriminator analysis.that SUMOylation of NR2E3may not be necessary for expression
of ESR1 in breast cancer cells. While previous studies have
identified Sp1 and TP53 as upstream regulators for ESR1
expression (Safe & Kim, 2004; Shirley et al, 2009), their roles in
breast cancer are not well understood. NR2E3 may interact with
them to regulate ESR1 expression, however, additional studies
are required to investigate the role of TP53 and Sp1 on regulation
of ESR1 expression by NR2E3 and PIAS3.
ESR1 has been used as a molecular marker for prognosis of
breast cancer and more importantly, as a predictive marker for
the benefits of anti-estrogen therapy with drug such as
tamoxifen treatment (Ali & Coombes, 2002; Loi et al, 2007).
However, not all ER-positive breast cancers respond to anti-www.embomolmed.org EMBO Mol Med 4, 52–67estrogen therapy, indicating that the clinical behaviour of ER-
positive breast cancer is heterogeneous despite detectable levels
of expression of ESR1 (Daidone et al, 2003; Loi, 2008; Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005).
Figure 7C and E shows that the expression level of the ESR1
alone does not solely explain the considerable differences in
clinical outcomes for patients with tumours that have
apparently similar histopathological features. Our current study
provides significant insight into clinical heterogeneity of ER-
positive breast cancer associated with response to tamoxifen
treatment (Fig 7D and F). The molecular mechanism associated
with the favourable response of ER-positive patients with a
higher expression of NR2E3 to tamoxifen therapy is currently 2011 EMBO Molecular Medicine 63
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64unclear. However, the requirement of NR2E3 for ESR1
expression suggests that high expression of NR2E3might reflect
a strong addiction of breast cancer cells to the ESR1 pathway for
survival and proliferation. Thus, ER-positive breast cancer cells
with high expression of NR2E3 might be more sensitive to
inhibition of ESR1 by anti-estrogen therapy.
To better understand existing interactions or to discover new
interaction among genes involved in malignant disease, it will
be necessary to take a systemic view of gene networks and to
develop new approaches to visualize such interactions. In our
current study, we demonstrated that systems-level reanalysis of
publicly available gene expression data uncovered unexpected
interactions of NRs and generated a new hypothesis that has
been tested by subsequent experiments. Moreover, our data
suggest that NR2E3 may be the ‘master’ regulator of ESR1 and
may dictate the clinical outcome of ER-positive breast cancer
treated with anti-estrogen therapies. Our current studies are
focused on NR2E3-mediated downstream genes and pathways
that are ESR1-dependent and -independent prognostic and
functional roles in breast cancer.MATERIALS AND METHODS
Cell lines
The MCF-7 and T47D human breast cancer cell lines were obtained
from American Type Culture Collection and maintained as described
previously (Zhang et al, 2005). To measure proliferation rate of breast
cancer cells, cells were stimulated with E2 or vehicle at the indicated
time in the presence of charcoal-stripped serum.
shRNA and siRNA
shNR2E3 (SHCLND-NM_014249) and shControl (SHC002) clones
were purchased from Sigma (St. Louis, MO). To express shRNA, we
transfected shRNA expression vectors into the cells using Lipofecta-
mine 2000 (Invitrogen, Carlsbad, CA). Twenty-four hours later,
transfected cells were selected for 10 days with 2mg/ml puromycin.
Sequences of siPIAS3 (Iwasaki et al, 2007), siESR1 (Li et al, 2003;
Zhang et al, 2005), siNCOA1 (Li et al, 2003) and siNCOA3 (Zhou et al,
2003) were described previously. siNCOA2 sequence is 50-CCU
GGA AGG CAA CGU UGU GUU-30 . siRNA SMART Pool was purchased
from Dharmacon. siRNA was transfected with the cells using
Oligofectamine (Invitrogen). Briefly, 30–50% confluent cells were
used for transfection. We transiently tranfected cells with siRNA
(20nM) for 2days and the cells were used for extraction of RNA
or protein.
qRT-PCR
To measure expression level of genes in cells, total RNA was extracted
from the indicated cell lines according to the manufacturer’s
instruction (mirVana RNA Isolation Kit; Ambion, Inc. Austin, TX), and
Polymerase Chain Reaction (after reverse transcription) (RT-PCR) was
assayed using real-time qRT-PCR with TaqMan primers specific to each
gene (Applied Biosystems, Foster City, CA). Real-time PCR was
performed using the 7700HT Real-Time PCR System with a 96-well
block module (Applied Biosystems). Cycling conditions were 458C for
30min and 958C for 10min, followed by 40 cycles of 958C for 15 s 2011 EMBO Molecular Medicineand 608C for 60 s. Relative amounts of mRNA were calculated from
the threshold cycle (CT) number using expression of cyclophilin A
(PPIA) as an endogenous control. All experiments were performed in
triplicate and the values were averaged.
Western blotting
To measure expression levels of proteins, cells were maintained and
Western blot was performed as described previously with an anti-
NR2E3 antibody (ARP39069; Aviva, San Diego, CA), PIAS3 antibody (SC-
46682; Santa Cruz Biotech, Santa Cruz, CA) and anti-ESR1 antibody
(RM-9101-S1; Neomarkers), NCOA1 (05-522; Upstate), NCOA2
(610984; BD Bioscience) and NCOA3 (612378; BD Bioscience), UBC9
(4918; Cell Signaling Technology) and b-actin (A5441) from Sigma.
Co-immunoprecipitation (IP)
Co-IP experiments were carried out as described previously (Peng
et al, 2009). In brief, whole-cell extracts from MCF-7 were prepared
in NP-40 buffer and precleaned with Protein A/G plus-agarose
beads (Santa Cruz Biotech). Cell extracts were then subjected to
incubation for 2 h with antibodies against NR2E3 (from Dr. Chen) or
PIAS3 (Santa Cruz; sc-46482 (or normal IgG; 5mg), followed by
incubation overnight with protein A/G-agarose beads at 48C. The
immunocomplex was eluted in loading buffer by being boiled for
5min at 958C and loaded on the SDS–polyacrylamide gel electro-
phoresis (SDS–PAGE).
Expression and purification of recombinant proteins
Human-NR2E3 cDNA was inserted by using EcoRI and XhoI sites of
pGEX4T1 and pET21-PIAS3 was described previously (Ban et al, 2011).
Escherichia coli BL21 (DE3) carrying the plasmid encoding GST-NR2E3
was cultured at 258C in LB medium supplemented with ampicillin
(100mg/ml). Isopropyl-1-thio-b-D-galactopyranoside (0.1mM) was
added and the culture was incubated for 5 h at 258C. GST-NR2E3
proteins were purified using glutathione–Sepharose (Amersham
Pharmacia). The His6-tagged PIAS3 was expressed in E. coli and were
purified with the use of an immobilized nickel resin (5Prime).
In vitro biding assay
The bead-immobilized His6-PIAS3 was incubated for 4 h at 48C with
GST-NR2E3 in 1ml of binding buffer consisting of 50mM Tris–HCl
(pH 7.6), 150mM NaCl and 10mM imidazole. The beads were then
washed four times with binding buffer and subjected to immunoblot
analysis with antibodies to the NR2E3 or PIAS3.
Plasmids and luciferase assay
pRK5-human NR2E3 and ESR1 promoters were described previously
(Chen et al, 2005; Sundar et al, 2008). Indicated cells were transfected
with reporter genes and indicated plasmids using Lipofectamine 2000
((Invitrogen) according to the manufacturer’s instruction. After 48 h,
cells were harvested to measure the luciferase activity, which was
normalized with b-gal.
Cell counting
Stably transfected cells were stimulated with 100nM estrogen for
24 h or in time course experiments for the time periods given in the
Fig 4E and F. Total cells were harvested for automated cell counting
using a Coulter Z1 counter.EMBO Mol Med 4, 52–67 www.embomolmed.org
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The paper explained
PROBLEM:
ESR1, a pivotal transcription factor regulating cell proliferation,
is one of the most well-known biomarker and an important
therapeutic target in breast cancer. While much is understood
about the molecular mechanisms underlying ESR1-downstream
target genes regulation, relatively little is known about how
expression of ESR1 is regulated in breast cancer.
RESULTS:
After generating a testable hypothesis by using a computational
approach to publicly available genomic and clinical data, the
authors have used biochemical and molecular biology techni-
ques to validate their theory and uncover possible clinically
relevant new findings. This strategy led to discover that orphan
nuclearreceptor NR2E3 is a novel upstream regulator of ESR1 in
breast cancer, and a potential biomarker for predicting a positive
prognosis to anti-hormone therapy.
IMPACT:
These findings provide novel insight into the mechanism of ESR1
regulation in breast cancer and open up new avenues for
developing novel predictive biomarker assay in response to anti-
hormone therapy.Chromatin Immunoprecipitation (ChIP)
ChIP assays were performed as described previously using the Upstate
EZ ChIP kit (Park et al, 2005; Peng et al, 2009; Millipore, Billerica, MA).
Anti-NR2E3 (received from Dr. Chen (Onishi et al, 2009). Anti-DHX-30
(Bethyl; a302-218A), Anti-PIAS3 (Santa Cruz; sc-46682) and control
IgG (Santa Cruz; sc-2763) were used for ChIP experiments. Primer
sequences used (governing ESR1 promoter region) were primer I
(forward) 50-GGGCCACCTTTAGCAGATC-30 (reverse) 50-CAGGGTGCA-
GACCGTGTC-30; primer II (forward) 50-GCTGGAGCCCCTGAACCGTCCGC-
30 (reverse) 50- GGCCCAGACTCCGACGCCGCA-30; and primer III
(forward) 50-CCCTGTGAGCAGACAGCAAGTC-30 (reverse) 50-AGAACAG-
CAATCCTCATCTCCCTGC-30 .
Reverse phase protein array (RPPA)
Human breast tumours were obtained from Tumour Banks following
pathologist review under the auspices of Institutional Review Board-
approved protocols at the M. D. Anderson Cancer Center (Stemke-Hale
et al, 2008). Protein extracts from breast cancer patients and RPPA
were performed as described previously (Stemke-Hale et al, 2008). To
quantify NR2E3 and ESR1 expression as a ratio to the total expression
of each protein, antibodies from Aviva (ARP39069) and Neomarkers
(RM-9101-S1, Sigma) were used (Fig S5 of Supporting Information).
Microarray
We transfected shRNA expression vectors (shCon. or shNR2E3) into
the cells using Lipofectamine 2000 (Invitrogen). Twenty-four hours
later, transfected cells were selected for 10 days with 1mg/ml
puromycin. Total RNA from these cells was extracted from the
indicated cell lines using a mirVana RNA Isolation Labeling kit
(Ambion, Inc.). Five hundred nanograms of total RNA were used for
labelling and hybridization according to the manufacturer’s protocols
(Illumina Inc., San Diego, CA). After the bead chips (Sentrix Human v.3
HT-12) were scanned with an Illumina BeadArray Reader (Illumina
Inc.), the microarray data were normalized using the quantile
normalization method in the Linear Models for Microarray Data
(LIMMA) package in the R language environment (Wright & Simon,
2003). The expression level of each gene was transformed into a log 2
base before additional analysis was performed (Lee et al, 2006). Allwww.embomolmed.org EMBO Mol Med 4, 52–67microarray data are available in NCBI’s Gene Expression Omnibus
public database (GSE18431). This microarray data was used for
analysis in Fig 8.
Gene expression data of breast cancer patients
Gene expression data from three-independent breast cancer patient
cohorts were used for analysis. Normalized gene expression data from
NKI and UNC cohort were obtained from pubic Merck website (http://
www.rii.com/publications/2002/nejm.html) and UNC microarray da-
tabase (https://genome.unc.edu), respectively. Gene expression data
from IJB cohort were obtained from Gene Expression Omnibus
(accession number GSE2990 and GSE6532) and normalized using
robust multi-array average methods (Irizarry et al, 2003).
Statistical analysis of microarray data and survival analysis
The random-variance t-test was applied to identify genes differentially
expressed between the two classes using Biometric Research Branch
(BRB) ArrayTools (National Cancer Institute, Bethesda, MD; Simon et al,
2007). Gene expression differences were considered statistically
significant if the p-value was less than 0.005. Cluster analysis was
performed with Cluster and Treeview (Eisen et al, 1998). Kaplan–Meier
plots and log-rank test were used to estimate patient prognosis.Author contributions
YYP, KK, SS and JSL conceived and designed this study; YYP and
KK performed the experiments; YYP and JSL analysed the
microarray data sets; SBK, ESP, SMK, JYL, WJ and GBM
contributed to the interpretation of the data; BTH, JL, YL and
AMGA performed the RPPA; YYP and JSL wrote the manuscript;
All authors approved the final version of this manuscript.Acknowledgements
We thank G. Firestone for providing the pGL3 ESR1 promoter
(Sundar et al, 2008) construct, Jeremy Nathans for providing
the pRK5-NR2E3 (Chen et al, 2005) construct, Takeshi Urano
for providing pET21-PIAS3 construct (Ban et al, 2011) and 2011 EMBO Molecular Medicine 65
Research Article
Novel regulator of ESR1 in breast cancer
66Shiming Chen for providing the NR2E3 antibody (Onishi et al,
2009). This work was supported by Bio R&D Program Grant
M10642040002-07N4204-00210, the Grant R01-2008-000-
11321-0 and the National Core Research Center Program Grant
R15-2006-020 funded by the National Research Foundation of
Korea (to W.J.).
Supporting information is available at EMBO Molecular
Medicine online.
The authors declare that they have no conflict of interest.References
Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies
for combating resistance. Nat Rev Cancer 2: 101-112
Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen
Y, Scudiero DA,Weinstein JN, et al (2008) Integrating global gene expression
and radiation survival parameters across the 60 cell lines of the National
Cancer Institute Anticancer Drug Screen. Cancer Res 68: 415-424
Ban R, Nishida T, Urano T (2011) Mitotic kinase Aurora-B is regulated by
SUMO-2/3 conjugation/deconjugation during mitosis. Genes Cells 16: 652-
669
Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ (2006)
Anatomical profiling of nuclear receptor expression reveals a hierarchical
transcriptional network. Cell 126: 789-799
Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W,
Hestermann EV, Geistlinger TR, et al (2005) Chromosome-wide mapping of
estrogen receptor binding reveals long-range regulation requiring the
forkhead protein FoxA1. Cell 122: 33-43
Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS,
Keeton EK, Fertuck KC, Hall GF, et al (2006) Genome-wide analysis of
estrogen receptor binding sites. Nat Genet 38: 1289-1297
Chen J, Rattner A, Nathans J (2005) The rod photoreceptor-specific nuclear
receptor Nr2e3 represses transcription of multiple cone-specific genes. J
Neurosci 25: 118-129
Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, Shuai K (1997) Specific inhibition
of Stat3 signal transduction by PIAS3. Science 278: 1803-1805
Cosman F, Lindsay R (1999) Selective estrogen receptor modulators: clinical
spectrum. Endocr Rev 20: 418-434
Daidone MG, Coradini D, Martelli G, Veneroni S (2003) Primary breast cancer
in elderly women: biological profile and relation with clinical outcome. Crit
Rev Oncol Hematol 45: 313-325
deGraffenried LA, Hilsenbeck SG, Fuqua SA (2002) Sp1 is essential for estrogen
receptor alpha gene transcription. J Steroid Biochem Mol Biol 82: 7-18
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of
chemotherapy and hormonal therapy for early breast cancer on recurrence
and 15-year survival: an overview of the randomised trials. Lancet 365:
1687-1717
Eeckhoute J, Keeton EK, LupienM, Krum SA, Carroll JS, BrownM (2007) Positive
cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in
breast cancer. Cancer Res 67: 6477-6483
Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and
display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:
14863-14868
Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or
progesterone receptor and pathologic characteristics of differentiation as
indicators of prognosis in node negative breast cancer patients: findings
from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.
J Clin Oncol 6: 1076-1087
Gronemeyer H, Gustafsson JA, Laudet V (2004) Principles for modulation of the
nuclear receptor superfamily. Nat Rev Drug Discov 3: 950-964 2011 EMBO Molecular MedicineHegele RA (2005) Retinoid X receptor heterodimers in the metabolic
syndrome. N Engl J Med 353: 2088
Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM
(1998) Time-dependence of hazard ratios for prognostic factors in primary
breast cancer. Breast Cancer Res Treat 52: 227-237
Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, James CR,
Farragher SM, Mulligan JM, Scott AN, et al (2007) Molecular basis for
estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl
Cancer Inst 99: 1683-1694
Hsu YC, Yuan S, Chen HY, Yu SL, Liu CH, Hsu PY, Wu G, Lin CH, Chang GC, Li KC,
et al (2009) A four-gene signature from NCI-60 cell line for survival
prediction in non-small cell lung cancer. Clin Cancer Res 15: 7309-7315
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E,
Dressler L, et al (2006) The molecular portraits of breast tumors are
conserved across microarray platforms. BMC Genomics 7: 96
Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP (2003) Summaries
of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15
Iwasaki K, Hailemariam K, Tsuji Y (2007) PIAS3 interacts with ATF1 and
regulates the human ferritin H gene through an antioxidant-responsive
element. J Biol Chem 282: 22335-22343
Jimenez-Lara AM, Heine MJ, Gronemeyer H (2002) PIAS3 (protein inhibitor of
activated STAT-3) modulates the transcriptional activation mediated by the
nuclear receptor coactivator TIF2. FEBS Lett 526: 142-146
Junicho A, Matsuda T, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, Fuse H,
Muraguchi A (2000) Protein inhibitor of activated STAT3 regulates
androgen receptor signaling in prostate carcinoma cells. Biochem Biophys
Res Commun 278: 9-13
Kanavos P (2006) The rising burden of cancer in the developing world. Ann
Oncol 17: viii15-viii23
Kobayashi M, Takezawa S, Hara K, Yu RT, Umesono Y, Agata K, Taniwaki M,
Yasuda K, Umesono K (1999) Identification of a photoreceptor cell-specific
nuclear receptor. Proc Natl Acad Sci USA 96: 4814-4819
Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M
(2008) Unique ERalpha cistromes control cell type-specific gene regulation.
Mol Endocrinol 22: 2393-2406
Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, Thorgeirsson SS (2004)
Application of comparative functional genomics to identify best-fit mouse
models to study human cancer. Nat Genet 36: 1306-1311
Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A,
Roberts LR, Demetris AJ, Sun Z, et al (2006) A novel prognostic subtype of
human hepatocellular carcinoma derived from hepatic progenitor cells.Nat
Med 12: 410-416
Li X, Wong J, Tsai SY, Tsai MJ, O’Malley BW (2003) Progesterone and
glucocorticoid receptors recruit distinct coactivator complexes and
promote distinct patterns of local chromatin modification. Mol Cell Biol 23:
3763-3773
Loi S (2008) Molecular analysis of hormone receptor positive (luminal) breast
cancers: What have we learnt? Eur J Cancer 44: 2813-2818
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A,
Bergh J, Foekens JA, et al (2007) Definition of clinically distinct molecular
subtypes in estrogen receptor-positive breast carcinomas through genomic
grade. J Clin Oncol 25: 1239-1246
Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C,
Ellis P, Ryder K, Reid JF, et al (2008) Predicting prognosis using molecular
profiling in estrogen receptor-positive breast cancer treated with
tamoxifen. BMC Genomics 9: 239
McKenna NJ, Cooney AJ, DeMayo FJ, Downes M, Glass CK, Lanz RB, Lazar
MA, Mangelsdorf DJ, Moore DD, Qin J, et al (2009) Minireview: evolution
of NURSA, the nuclear receptor signaling atlas. Mol Endocrinol 23: 740-
746
Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley
J, Cronise P, Vaigro-Wolff A, et al (1991) Feasibility of a high-flux anticancer
drug screen using a diverse panel of cultured human tumor cell lines. J Natl
Cancer Inst 83: 757-766EMBO Mol Med 4, 52–67 www.embomolmed.org
Research Article
Yun-Yong Park et al.Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM (2006)
Estrogen-regulated genes predict survival in hormone receptor-positive
breast cancers. J Clin Oncol 24: 1656-1664
Onishi A, Peng GH, Hsu C, Alexis U, Chen S, Blackshaw S (2009) Pias3-
dependent SUMOylation directs rod photoreceptor development. Neuron
61: 234-246
Park YY, Ahn SW, Kim HJ, Kim JM, Lee IK, Kang H, Choi HS (2005) An
autoregulatory loop controlling orphan nuclear receptor DAX-1 gene
expression by orphan nuclear receptor ERRgamma. Nucleic Acids Res 33:
6756-6768
Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W,
Lu Y, Woo HG, et al (2010) Davies MA Integrative analysis of proteomic
signatures, mutations, and drug responsiveness in the NCI 60 cancer cell
line set. Mol Cancer Ther 9: 257-267
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron
C, He X, Hu Z, et al (2009) Supervised risk predictor of breast cancer based on
intrinsic subtypes. J Clin Oncol 27: 1160-1167
Peng G, Yim EK, Dai H, Jackson AP, Burgt I, Pan MR, Hu R, Li K, Lin SY (2009)
BRIT1/MCPH1 links chromatin remodelling to DNA damage response. Nat
Cell Biol 11: 865-872
Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R, Cragun J, Cottrill H,
Kelley MJ, Petersen R, et al (2006) Genomic signatures to guide the use of
chemotherapeutics. Nat Med 12: 1294-1300
Reinhold WC, Mergny JL, Liu H, Ryan M, Pfister TD, Kinders R, Parchment R,
Doroshow J, Weinstein JN, Pommier Y, et al (2010) Pommier Y Exon array
analyses across the NCI-60 reveal potential regulation of TOP1 by
transcription pausing at guanosine quartets in the first intron. Cancer Res
70: 2191-2203
Safe S, Kim K (2004) Nuclear receptor-mediated transactivation through
interaction with Sp proteins. Prog Nucleic Acid Res Mol Biol 77: 1-36
Sakaguchi K, Koshiyama A, Iwabata K (2007) Meiosis and small ubiquitin-
related modifier (SUMO)-conjugating enzyme, Ubc9. FEBS J 274: 3519-
3531
Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold
WC, Myers TG, Andrews DT, et al (2000) A gene expression database for the
molecular pharmacology of cancer. Nat Genet 24: 236-244
Schorderet DF, Escher P (2009) NR2E3 mutations in enhanced S-cone
sensitivity syndrome (ESCS), Goldmann-Favre syndrome (GFS), clumped
pigmentary retinal degeneration (CPRD), and retinitis pigmentosa (RP).
Hum Mutat 30: 1475-1485
Shirley SH, Rundhaug JE, Tian J, Cullinan-Ammann N, Lambertz I, Conti CJ,
Fuchs-Young R (2009) Transcriptional regulation of estrogen receptor-www.embomolmed.org EMBO Mol Med 4, 52–67alpha by p53 in human breast cancer cells. Cancer Res 69: 3405-
3414
Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug
screen. Nat Rev Cancer 6: 813-823
Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y (2007) Analysis of gene
expression data using BRB-array tools. Cancer Inform 3: 11-17
Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M,
Carey M, Hu Z, Guan Y, Sahin A, et al (2008) An integrative genomic and
proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Cancer Res 68: 6084-6091
Sundar SN, Marconett CN, Doan VB, Willoughby JA, Sr Firestone GL (2008)
Artemisinin selectively decreases functional levels of estrogen receptor-
alpha and ablates estrogen-induced proliferation in human breast cancer
cells. Carcinogenesis 29: 2252-2258
Takezawa S, Yokoyama A, Okada M, Fujiki R, Iriyama A, Yanagi Y, Ito H, Takada
I, Kishimoto M, Miyajima A, et al (2007) A cell cycle-dependent co-repressor
mediates photoreceptor cell-specific nuclear receptor function. EMBO J 26:
764-774
Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F,
Helgeson BE, Laxman B, Morris DS, et al (2008) The role of SPINK1 in ETS
rearrangement-negative prostate cancers. Cancer Cell 13: 519-528
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ,
Peterse JL, Roberts C, MartonMJ, et al (2002) A gene-expression signature as
a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009
Wang YP, Li KB (2009) Correlation of expression profiles between microRNAs
and mRNA targets using NCI-60 data. BMC Genomics 10: 218
Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H,
Lupien M et al (2009) Androgen receptor regulates a distinct transcription
program in androgen-independent prostate cancer. Cell 138: 245-256
Wright GW, Simon RM (2003) A random variance model for detection of
differential gene expression in small microarray experiments.
Bioinformatics 19: 2448-2455
Xu J, Wu RC, O’Malley BW (2009) Normal and cancer-related functions of the
p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer 9: 615-630
Yang X, Downes M, Yu RT, Bookout AL, He W, Straume M, Mangelsdorf DJ,
Evans RM (2006) Nuclear receptor expression links the circadian clock to
metabolism. Cell 126: 801-810
Zhang S, Li X, Burghardt R, Smith R, III, Safe SH (2005) Role of estrogen
receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses
in MCF-7 breast cancer cells. J Mol Endocrinol 35: 433-447
Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai MJ (2003) Role of the steroid
receptor coactivator SRC-3 in cell growth. Mol Cell Biol 23: 7742-7755 2011 EMBO Molecular Medicine 67
